Company
Xenon Pharmaceuticals Inc.
Headquarters: Burnaby, BC, Canada
Employees: 149
CEO: Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA
Market Cap
$2.55 Billion
USD as of July 1, 2025
Xenon Pharmaceuticals Inc. Categories
Canada Healthcare BiotechnologyCanada Healthcare Canada Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | $7.5 M |
| EBITDA | $-290,361,984 |
| Gross Profit TTM | $-219,844,000 |
| Profit Margin | 0.00% |
| Operating Margin | -969.84% |
| Quarterly Revenue Growth | % |
Stocks & Indices
Xenon Pharmaceuticals Inc. has the following listings and related stock indices.
Stock: NASDAQ: XENE wb_incandescent
Stock: FSX: XP0 wb_incandescent